New Study Reports That Ablative Therapy With HALO360 Device Effectively Treats Highest-Risk Category Of Barrett’s Esophagus

BARRX Medical, Inc., the global technology leader for treating precancerous conditions of the digestive tract, announced that 90.2 percent of the patients in a multi-center U.S. study were free of the highest-risk of Barrett’s esophagus after having a non-surgical, endoscopic treatment using the HALO360 ablation system. Barrett’s esophagus afflicts more than three million U.S. adults and is a complication of gastroesophageal reflux disease (GERD).

More: continued here

Filed under: Cancer on May 18th, 2008